# Lek Pharmaceuticals, Ljubljana, Slovenia – FDA Inspections

Source: https://www.keypedia.com/companies/lek-pharmaceuticals/6b651b9c-9e4f-46ac-a02a-ddc22f9bc3a6

> Inspection records and compliance data for Lek Pharmaceuticals in Ljubljana. 9 FDA inspections on record, 2 Form 483s, last inspected July 26, 2024.

---

## Details

- Name: Lek Pharmaceuticals
- FEI Number: 3002807460
- Business Operations: API/FDF ANALYTICAL TESTING, FDF MANUFACTURE, IN VITRO BIOEQUIVALENCE OR BIOANALYTICAL TESTING, PACK, REPACK
- Address Line 1: Verovskova Ulica 57
- City: Ljubljana
- Country Name: Slovenia
- Address: Verovskova Ulica 57, Ljubljana, Slovenia
- Country: Slovenia

## Related Documents

- FDA Inspection 1246916 - Lek Pharmaceuticals - 2024-07-26 — classification: No Action Indicated (NAI), source: FDA, date: July 26, 2024
- FDA Inspection 1254088 - Lek Pharmaceuticals - 2023-12-11 — classification: No Action Indicated (NAI), source: FDA, date: December 11, 2023
- [FDA Inspection 1178973 - Lek Pharmaceuticals - 2022-03-18](https://www.keypedia.com/records/fda_inspections/lek-pharmaceuticals/45b6f40d-76b3-4a3a-ba54-df7addeaffc4) — classification: Voluntary Action Indicated (VAI), source: FDA, date: March 18, 2022
- [FDA Inspection 1045912 - Lek Pharmaceuticals - 2018-02-20](https://www.keypedia.com/records/fda_inspections/lek-pharmaceuticals/1c205713-c9e8-42a5-aac4-7e8e5a858fac) — source: FDA, date: February 20, 2018
- [FDA Inspection 1005712 - Lek Pharmaceuticals - 2017-02-24](https://www.keypedia.com/records/fda_inspections/lek-pharmaceuticals/86ecc7de-f878-448b-910f-cb7f2cb553f8) — classification: Voluntary Action Indicated (VAI), source: FDA, date: February 24, 2017
- FDA Inspection 1005712 - Lek Pharmaceuticals - 2017-02-24 — classification: Voluntary Action Indicated (VAI), source: FDA, date: February 24, 2017
- [FDA Inspection 935159 - Lek Pharmaceuticals - 2015-06-30](https://www.keypedia.com/records/fda_inspections/lek-pharmaceuticals/0a8fc7e3-f9f4-434f-878a-68b96987e873) — classification: Voluntary Action Indicated (VAI), source: FDA, date: June 30, 2015
- FDA Inspection 848663 - Lek Pharmaceuticals - 2013-09-13 — classification: Voluntary Action Indicated (VAI), source: FDA, date: September 13, 2013
- [FDA Inspection 779021 - Lek Pharmaceuticals - 2012-04-06](https://www.keypedia.com/records/fda_inspections/lek-pharmaceuticals/722555c1-703e-47b6-be9e-48df47a35d48) — classification: Voluntary Action Indicated (VAI), source: FDA, date: April 6, 2012
- FDA Inspection 644510 - Lek Pharmaceuticals - 2009-10-01 — classification: Voluntary Action Indicated (VAI), source: FDA, date: October 1, 2009

## Related Companies

- [Eurofins Advantar Laboratories, Inc](https://www.keypedia.com/companies/eurofins-advantar-laboratories-inc/fe88e38f-0ce0-4e6e-a1bb-ed73634ac024)
- [Visum Pharmaceutical Co Ltd](https://www.keypedia.com/companies/visum-pharmaceutical-co-ltd/304efe69-24b4-4b93-aece-f7addcc5e21c)
- [Opella Healthcare International SAS](https://www.keypedia.com/companies/opella-healthcare-international-sas/53ed93ee-b631-49a0-bba2-a57194143394)
- [EirGen Pharma Ltd](https://www.keypedia.com/companies/eirgen-pharma-ltd/f9a682ae-b665-4341-814c-af610c74a3ec)
- [ANSTO Nuclear Medicine](https://www.keypedia.com/companies/ansto-nuclear-medicine/9bb26b43-b1c1-4d57-9008-7563e01d67e2)
- [Zydus Hospira Oncology Private Ltd.](https://www.keypedia.com/companies/zydus-hospira-oncology-private-ltd/1daf2047-24d1-4343-9500-8a3c69eccaf4)
- [Kindos Pharmaceuticals Co., Ltd.](https://www.keypedia.com/companies/kindos-pharmaceuticals-co-ltd/a5fd0a47-2dba-4a4d-a030-877525533def)
- [Boehringer Ingelheim Espana S.A.](https://www.keypedia.com/companies/boehringer-ingelheim-espana-sa/afd6c8fe-92cc-4db4-8157-94020bcf06d6)
- [R-Pharm Germany GmbH](https://www.keypedia.com/companies/r-pharm-germany-gmbh/00237a65-957b-4892-abce-2844ed37acda)
- [Sofgen Pharmaceuticals LLC](https://www.keypedia.com/companies/sofgen-pharmaceuticals-llc/4bf867c1-4886-43a8-b3a1-3d027c2307b8)